Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28026121 | 1.00 | KMT2A (0.55) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL5835956 | 0.93 | KMT2A (0.51) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL5835964 | 0.92 | KMT2A (0.50) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL16870979 | 0.85 | KMT2A (0.53) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL9687500 | 0.83 | MMP8 (0.49) | KMT2ALMNAMEN1TSHRSLC6A3 | |
| SCHEMBL7218494 | 0.82 | HDAC4 (0.44) | KMT2ALMNAPTGS1PTGS2ALDH1A1 | |
| SCHEMBL7218493 | 0.82 | HDAC4 (0.44) | KMT2ALMNAPTGS1PTGS2ALDH1A1 | |
| SCHEMBL9563164 | 0.80 | LMNA (0.53) | KMT2ALMNAALDH1A1CYP2C19CYP3A4 | |
| SCHEMBL9686992 | 0.80 | KMT2A (0.47) | KMT2ALMNAPTGS1PTGS2MEN1 | |
| SCHEMBL5836538 | 0.80 | LMNA (0.51) | LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105801415-A | Fluorine-containing chiral allylic compound and preparation method thereof | 同济大学 | 2016-07-27 | — | — | CN | disclosed |
| CN-102731572-B | Containing the Phosphine ligands of perfluoroalkyl, its preparation method, application and metal complex | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2015-08-05 | — | — | CN | disclosed |
| US-8058429-B2 | Diazaphosphacycle transition metal complexes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100222583-A1 | DIAZAPHOSPHACYCLE TRANSITION METAL COMPLEXES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2010-09-02 | — | — | US | disclosed |
| US-7737272-B2 | Diazaphosphacycle transition metal complexes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737272-B2 | Diazaphosphacycle transition metal complexes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-7507820-B2 | Diazaphosphacycles | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507820-B2 | Diazaphosphacycles | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080146798-A1 | DIAZAPHOSPHACYCLE TRANSITION METAL COMPLEXES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| US-20080146798-A1 | DIAZAPHOSPHACYCLE TRANSITION METAL COMPLEXES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| US-6747152-B2 | COMPRISES MOLYBDENUM/TUNGSTEN/CHROMIUM COMPLEXES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2004-06-08 | — | — | US | disclosed |
| US-20030191340-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-09 | — | — | US | disclosed |
| EP-1049537-B1 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALLYLIC ALKYLATION | UNIV LELAND STANFORD JUNIOR (US) | 2003-08-06 | — | — | EP | disclosed |
| US-6541655-B2 | For use in regioselective and enantioselective alkylations of allylic substrates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2003-04-01 | — | — | US | disclosed |
| US-20020198383-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-26 | — | — | US | disclosed |
| EP-1049537-A2 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALLYLIC ALKYLATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-11-08 | — | — | EP | disclosed |
| US-6130349-A | USING COMPLEX OF MOLYBDENUM, TUNGSTEN OR CHROMIUM WITH 1,1*-BINAPHTHYL SYSTEM CONTAINING HETEROCYCLIC NITROGEN GROUP; ENANTIO- AND REGIOSELECTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-10-10 | — | — | US | disclosed |
| WO-1999032225-A9 | CATALYTIC COMPOSITION BASED ON CHIRAL LIGANDS WITH MOLYBDENUM, TUNGSTEN OR CHROMIUM AND METHOD FOR ASYMMETRIC ALKYLATION OF ALLYLIC SUBSTRATES | UNIV LELAND STANFORD JUNIOR (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999032225-A2 | CATALYTIC COMPOSITION BASED ON CHIRAL LIGANDS WITH MOLYBDENUM, TUNGSTEN OR CHROMIUM AND METHOD FOR ASYMMETRIC ALKYLATION OF ALLYLIC SUBSTRATES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5147952-A | PROCESS FOR PRODUCING MACROMOLECULAR MONOMER | TOAGOSEI CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146798-A1 | DIAZAPHOSPHACYCLE TRANSITION METAL COMPLEXES | MCM3, MT-ND3, IDH3A | KMT2A 3371/4885LMNA 2710/4885PTGS1 2301/4885 |
| US-20100222583-A1 | DIAZAPHOSPHACYCLE TRANSITION METAL COMPLEXES | MCM3, MT-ND3, IDH3A | KMT2A 3371/4885LMNA 2710/4885PTGS1 2301/4885 |
| US-20020198383-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | MPG, UNG, APOBEC3C | KMT2A 1585/4885LMNA 3748/4885PTGS1 4633/4885 |
| US-20030191340-A1 | Catalytic compositions and methods for asymmetric allylic alkylation | MPG, UNG, APOBEC3C | KMT2A 1585/4885LMNA 3748/4885PTGS1 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.